1	Trikafta therapy alters the CF lung mucus metabolome reshaping microbiome niche space
2	
3	Lauren M. Sosinski <sup>1</sup> , Christian Martin H. <sup>1</sup> , Kerri A. Neugebauer <sup>1</sup> , Lydia-Ann J. Ghuneim <sup>1</sup> , Douglas V.
4	Guzior <sup>1,2</sup> , Alicia Castillo-Bahena <sup>3</sup> , Jenna Mielke <sup>4</sup> , Ryan Thomas <sup>5</sup> , Marc McClelland <sup>3</sup> , Doug Conrad <sup>4</sup> and
5	Robert A. Quinn <sup>1</sup> *
6	
7	<sup>1</sup> Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA.
8 9	<sup>2</sup> Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA.
10	<sup>3</sup> Spectrum Health, Grand Rapids, MI, USA
11	<sup>4</sup> Department of Medicine, University of California San Diego, La Jolla, CA
12	<sup>5</sup> Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA
13	
14	* To whom the correspondence should be addressed: Robert Quinn. Department of Biochemistry and
15	Molecular Biology, Michigan State University, East Lansing, Michigan, USA. Email:
16	<u>quinnrob@msu.edu</u>
17	
18	Author contributions: LS, CMH, KN, LJG, DVG generated data; LS, CMH, KN and RAQ analyzed data,
19 20	ACB, JM collected samples: MM, RT and DC recruited patients; LM, CMH, KN, and RAQ wrote the
20	paper; RAQ obtained funding for the project
21	Sources of support: NIH R01411/5925
22	Running head: TRIKAETA Microbiome and Metabolome Dynamics in CE
23	
25	
26	
27	
28	
29	

### 30 Abstract

Background: Novel small molecule therapies for cystic fibrosis (CF) are showing promising efficacy and becoming more widely available since recent FDA approval. The newest of these is a triple therapy of Elexacaftor-Tezacaftor-Ivacaftor (ETI, Trikafta®). Little is known about how these drugs will affect polymicrobial lung infections, which are the leading cause of morbidity and mortality among people with CE (pwCE)

35 CF (pwCF).

Methods: we analyzed the sputum microbiome and metabolome from pwCF (n=24) before and after
 ETI therapy using 16S rRNA gene amplicon sequencing and untargeted metabolomics.

38 **Results**: The lung microbiome diversity, particularly its evenness, was increased (p = 0.044) and the 39 microbiome profiles were different between individuals before and after therapy (PERMANOVA F=1.92, 40 p=0.044). Despite these changes, the microbiomes were more similar within an individual than across 41 the sampled population. There were no specific microbial taxa that were different in abundance before 42 and after therapy, but collectively, the log-ratio of anaerobes to classic CF pathogens significantly 43 decreased. The sputum metabolome also showed changes due to ETI. Beta-diversity increased after 44 therapy (PERMANOVA F=4.22, p=0.022) and was characterized by greater variation across subjects 45 while on treatment. This significant difference in the metabolome was driven by a decrease in peptides, 46 amino acids, and metabolites from the kynurenine pathway. Metabolism of the three small molecules 47 that make up ETI was extensive, including previously uncharacterized structural modifications.

48 **Conclusions**: This study shows that ETI therapy affects both the microbiome and metabolome of 49 airway mucus. This effect was stronger on sputum biochemistry, which may reflect changing niche 50 spaces for microbial residency in lung mucus as the drug's effects take hold, which then leads to 51 changing microbiology.

Funding: This project was funded by a National Institute of Allergy and Infectious Disease GrantR01AI145925

54 Keywords: Cystic Fibrosis, sputum, microbiome, metabolome, Trikafta

55

#### 56 Introduction

57 Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis 58 transmembrane conductance regulator (CFTR) gene. CFTR is a cAMP-regulated ion channel used for 59 the transport anions across epithelial cells (1). Mutations in this gene cause a thickening of mucosal 60 secretions, primarily in the respiratory and gastrointestinal systems, and chronic polymicrobial infection 61 of the airways (1). Common clinical representations of this disease include, but are not limited to, 62 increased polymicrobial infections, infertility, decreased lung function, and pancreatic insufficiency (1). 63 Pancreatic sufficiency is inherently linked to the specific mutation class, but other aspects of CF 64 pathology have unclear links to genotype (2, 3). It is clear however, that those with severe disease, 65 especially the delF508 mutation, are plaqued by chronic lung infection throughout their lifetime (4).

The lung microbiome of people with CF (pwCF) has been well characterized and includes bacteria, viruses, and fungi (5–7). Studies of sputum expectorated from the airways have demonstrated that the CF lung microbiome diversity decreases as the disease progresses over time, becoming dominated by opportunistic pathogens, such as *Pseudomonas aeruginosa (4, 8)*. Thickened mucus within the lungs allows for these pathogens to form a biofilm and thrive *(9)*. The chemical composition of this matrix has been shown to mainly include DNA, amino acids, peptides, antibiotics, inflammatory lipids, and a myriad of small molecules from host, microbial, and xenobiotic sources *(10–14)*.

73 In November 2019, a new triple therapy drug Elexacaftor-Tezacaftor-Ivacaftor (ETI, Trikafta®) 74 was approved by the United States Food and Drug Administration (FDA) for the treatment of CF (15). 75 ETI is composed of three different compounds: Tezacaftor, Elexacaftor, and Ivacaftor (16). People with 76 at least one copy of the F508del mutation, which is the most common mutation across CF patients, are 77 eligible to take ETI. Studies from clinical trials and data available since approval have shown that the 78 treatment is providing remarkable improvements in lung function and other disease symptoms (17, 18). 79 Little is known, however, about how this new therapy will affect the CF lung microbiome and 80 metabolome.

In this study, sputum samples from pwCF (n=24) were collected before and after therapy (within one year of FDA approval) and analyzed using an integrated multi-omics approach including 16S rRNA amplicon sequencing and LC-MS/MS untargeted metabolomics. Changes in both microbiome and metabolome were identified and indicate a significant shift in the niche space of airway mucus and its microbial occupancy from ETI therapy.

### 86 Methods

87 Further detail available in supplemental methods.

88 Sample Collection. Sputum samples were collected during routine clinical visits from adult pwCF (>18 89 years) at two separate CF clinics (patient details table S1). Samples were obtained from the most 90 recent clinical visit prior to ETI administration and the most recent visit after ETI administration if 91 sputum production was possible. Ethical approval for the collections at the University of California San 92 Diego adult CF clinic was obtained from the UCSD Human Research Protections Program Institutional 93 Review Board under protocol #160078. Institutional review board approval was also provided for the 94 collections at the Spectrum Health adult CF clinic in Grand Rapids, MI by the Spectrum Health Human 95 Research Protection Program Office of the Institutional Review Board under IRB #2018-438.

96 DNA Extraction, qPCR, and 16S rRNA single amplicon sequencing. A Qiagen® PowerSoil® DNA 97 extraction kit was used to extract DNA from the sputum samples following standard protocol. PCR 98 amplification was then performed using 27F and 1492R primers targeting the bacterial 16S rRNA gene 99 to test for DNA amplification quality. Bacterial 16S rRNA V4 amplicon sequencing was performed with 100 primers 515f/806r on an Illumina® MiSeq® at the Michigan State University Sequencing Core. The raw 101 sequences were processed using QIITA (giita.ucsd.edu( (19), which is driven by QIIME2 algorithms 102 (20), and quality filtered to generate amplicon sequence variants (ASVs) through the deblur method 103 (21). ASVs in the microbiome data were classified as 'classic CF pathogens' or 'anaerobes' based on 104 the methods of Raghuvanshi et al. (2020) and Carmody et al. (2018) (22, 23). The specific ASVs and 105 their classifications are available in table S2. gPCR was executed using universal 16S primers (43) and 106 Applied Biosystems SYBR Green PCR Master Mix with three technical replicates were obtained for 107 each sample. The microbiome data is publicly available at the Qiita repository under study #13507.

108

109 Metabolomics. Organic metabolite extraction was performed by adding twice the sample volume of 110 chilled 100% methanol, vortexing briefly, and incubating at room temperature for 2 hours. Samples 111 were then centrifuged at 10,000 x g and the supernatant was collected. Methanolic extracts were 112 analyzed on a Thermo Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometer coupled to a 113 Vanguish ultra-high-performance liquid chromatography system. All raw files were converted to 114 .mzXML format and then processed with MZmine 2.53 software (24), GNPS molecular networking (25) and SIRIUS (26). MZmine 2 parameters are available in the supplementary information (Table S3). The 115 116 network job is available at

117 <u>https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=c700397169ff447490f764c34abb5abd</u> and the

118 mass spectrometry data were deposited on public repository <u>massive.ucsd.edu</u> under MassIVE ID

- 119 <u>MSV000087364</u>.
- 120

121 Statistical Analysis. Statistical approaches for both the microbiome and metabolome data were 122 similar, due to the inherent structural similarity of the multivariate data sets. Normality of the different 123 quantitative measures was first tested using a Shapiro-Wilk (SW) test in order to determine appropriate 124 statistical methods. If the data was normally distributed, a paired dependent means t-test (DM t-test) 125 was used. Otherwise, a Wilcoxon signed-rank test (WSRT) was used. Alpha-diversity was calculated 126 for both datasets using the Shannon index. Beta-diversity measures were calculated using the 127 weighted UniFrac distance for the microbiome and Bray-Curtis distance for the metabolome. Beta-128 diversity was visualized for both datasets using principal coordinates analysis (PCoA) and the EMPeror 129 software (27). Beta-diversity clustering significance pre- and post-ETI were tested using a 130 Permutational Multivariate Analysis of Variance (PERMANOVA) method with 999 permutations. Cross 131 population beta-diversity comparisons were done between pwCF before ETI therapy, after therapy, 132 across the whole dataset, and within individuals pre- and post-therapy.

To identify metabolite and microbial drivers of the difference pre- and post-therapy, a random forest (RF) machine learning approach was used via the randomForest package in R *(28)*. The top 50 variables of importance were further explored. As all individual metabolite and microbiome abundance data were not considered normally distributed, statistical significance for individual microbial and metabolite changes before and after ETI treatment were calculated using the WRST. The p-values were adjusted for multiple comparisons using the Benjamini-Hochberg method.

139 Microbe and metabolite association vectors were calculated using mmvec *(29)*. Detail of the 140 mmvec paramaters and analysis is available in the online supplmement.

141

## 142 **Results**

143

144 Microbiome and Metabolome Diversity Changes from ETI Treatment. Shannon diversity and 145 number of ASVs of the microbiome showed an increase between samples collected before and after 146 ETI treatment, but this did not reach statistical significance (Shannon SW normality p=0.238, WSRT 147 p=0.062; Number of ASVs SW normality p=0.0043, DM t-test p=0.12, Fig. 1a). The Pielou evenness, 148 however, was significantly higher post-therapy than before ETI (SW normality p=0.074, WSRT 149 p=0.044). The metabolome did not show a significant change in Shannon index after ETI therapy (SW 150 p=0.0017, DM t-test, p=0.45, Fig. 1b) or evenness (Pielou evenness SW p=0.13, DM t-test p=0.30). 151 However, the number of molecular features did decrease after therapy (SW p=0.0027 DM t-test 152 p=0.010). Collectively, this alpha-diversity analysis demonstrates that new ASVs were not being

153 introduced into the sputum microbiome, but rather became more even with previously present taxa. In

regard to the alpha-diversity of the metabolome, there was a decrease in the total number of

155 metabolites present.

156 PCoA plots were used to visualize beta-diversity differences between samples of the two data 157 types (Fig. 1c, d). In both the microbiome and metabolome, there was a cluster of more similar samples 158 and a spread along the first and second axis indicating samples with greater diversity. PERMANOVA 159 testing showed that the microbiome profile of the sputum samples changed after ETI treatment 160 (p=0.044). The metabolome profile also changed significantly after treatment (p=0.002), with a stronger 161 metric of difference in the metabolome compared to the microbiome (F-value=1.92 microbiome, F-162 value=3.12 metabolome, Fig. 1c, d). There was statistically significant movement along the first 163 principal coordinate axis after ETI therapy for both the microbiome (SW test p=0.02, DM t-test 164 p=0.0027) and the metabolome (SW p=0.0011, DM t-test p=0.00071) indicating that changes in these 165 measures occurred similarly within this beta-diversity space. There was no significant change along the 166 second axis. The beta-diversity differences among samples were also compared before, between, and 167 after ETI treatment across subjects and within subjects (SW normality on beta-diversity distributions microbiome  $p=1.4 \times 10^{-15}$ , metabolome  $p=2.2 \times 10^{-16}$ ). The microbiome showed the smallest change 168 169 within subjects before and after therapy than across subjects at any period, indicating that although the 170 microbiome profiles change significantly (Fig. 1e), there was still more similarity within an individual 171 before and after therapy than across the population no matter the treatment category. The metabolome 172 beta-diversity comparisons showed different trends than the microbiome. The largest beta-diversity in 173 metabolite profiles was seen across patients in samples collected after therapy, signifying that the 174 chemical makeup of sputum becomes far more varied across people once administered ETI (Fig. 1f). In 175 contrast, the metabolomes were the most similar across subjects prior to ETI therapy, indicating that 176 sputum metabolite profiles were relatively similar prior to ETI administration, but varied greatly across 177 individuals after treatment.

178

179 Microbial Changes After ETI Treatment. A random forest classification was used to determine how 180 well the microbiome data reflected the pre- or post-treatment groups and to rank the ASVs by their 181 contribution to that classification. Overall, the random forest model poorly classified the microbiome 182 data with an error rate of 44.7%. Veillonella parvula and Staphylococcus sp. were ASVs with strong 183 classifiers (Table S4) with a high overall abundance. However, none of the ranked ASVs were 184 significantly different between pre- and post-treatment samples after correction for false-discovery 185 (Benjamini-Hochberg corrected, WSRT p>0.05). The ASV representing Pseudomonas showed 186 dynamic changes in some individuals, but it was not significantly different in the overall paired data (Fig. 187 2). Similarly, at the family level, there was no significant difference before and after therapy following

188 false discovery rate correction. We also summed the abundance of all 'CF pathogens' and 'anaerobes'

189 (as described in table S2) and compared the log-ratio of pathogens/anaerobes, as described by

190 Raghuvanshi et al. (2020) (22), and found it significantly decreased following ETI therapy (SW p =

191 0.233, WSRT p = 0.013, Fig. 2).

192 A qPCR assay using universal primers for the bacterial 16S rRNA gene (43) was used to 193 calculate the total number of rRNA copies/mL of sputum pre- and post-therapy. The mean prior to 194 therapy was  $1.17 \times 10^9$  copies/mL and after therapy was  $7.62 \times 10^8$  copies/mL. This difference was not 195 statistically significant but did show a decreasing trend (SW p = 0.0027, DM t-test p = 0.061, Fig. 2).

196

Metabolite Changes After ETI Treatment. Annotated metabolites were first grouped into molecular families and summed to determine overall changes. This analysis showed the major metabolomic signature due to ETI therapy was a decrease in peptides and amino acids. Though phosphocholine and phosphoethanolamine abundance did not change before and after ETI, peptide and amino acid abundance significantly decreased (Fig. 3a). This demonstrates an overall change in the relative abundance of this compound class, while other classes remained static.

203 A random forest machine learning classification was used to assess how well the complete 204 metabolomic data reflected changes after ETI therapy. The out-of-bag error rate of the classification 205 was 22.92% indicating that there was a metabolomic signal for ETI therapy, but not all samples were 206 correctly classified as pre- or post-treatment. The importance of each metabolite in the construction of 207 the random forest model was produced, noting the impact of each metabolite on differentiating pre- and 208 post-treatment groups (Table S5). Of the 50 most important classifiers, 13 were annotated in the GNPS 209 database and of those, 10 were annotated as amino acids or peptides. These were primarily 210 dipeptides, including Phe-Glu, Ile-Leu, Glu-Val, and Ser-Phe, as well as the amino acid tryptophan; all 211 of which significantly decreased after ETI therapy (Fig 1b). Molecular network analysis (Fig. 3c) showed 212 a diverse set of peptides that were more abundant prior to ETI therapy. Metabolites from the 213 kynurenine pathway (which includes tryptophan) were also identified as strong classifyers in the model. 214 Kynurenine, formylkynurenine, and indole abundance significantly decreased after ETI therapy (Fig. 215 3b). The *P. aeruginosa* siderophore pyochelin was detected in only 10 of the 24 patients. Comparing 216 pyochelin abundance within those 10 individuals showed that it significantly decreased after ETI 217 therapy as well (Fig. 3b). Though commonly detected in CF sputum with the metabolomics methods 218 used here, other P. aeruginosa specialized metabolites were not detected in this study, except for one 219 quinolone (NHQ) that was detected in 6 samples.

220

221 Trikafta Metabolism in CF Mucus. ETI is a triple therapy of the compounds lyacaftor, Elexacaftor, and 222 Tezacaftor. All three drugs were identified in the sputum metabolome by MS/MS analysis with similar 223 fragmentation behavior to that described by Reves-Ortega et al. (2020) (30). This included the known 224 and unknown metabolized products of the parent drugs with related MS/MS spectra (Fig. 4). Ivacaftor 225 had extensive metabolism revealed by molecular networking with the parent drug having six related 226 nodes with unique retention times. Two of these are known, M1 and M6, as hydroxymethyl ivacaftor 227 and ivacaftor carboxylate, respectively. Other modifications of the compounds were also seen, 228 including further hydroxylations and carboxylations. Tezacaftor metabolism was also identified. This 229 included dehydrogenation (metabolite M1, m/z 519.1400, C<sub>26</sub>H<sub>26</sub>F<sub>3</sub>N<sub>2</sub>O<sub>6</sub>+H<sup>+</sup>). Also detected, but not 230 shown, was a phosphorylated metabolite (m/z 599.1401,  $C_{26}H_{27}F3N_2O_9P+H^+$ ) and a known glucuronate 231 (metabolite M3, Fig. 4a). Elexacaftor exhibited only one metabolic transformation – the loss of a methyl 232 group on its pyrazole ring (Fig. 4).

233 Ivacaftor and Tezacaftor were detected in sputum samples both prior to and after ETI 234 administration. These two compounds were released as therapies in prior formulations of CFTR 235 correctors, likely explaining their presence. Elexacaftor, the next generation corrector unique to ETI, 236 was present in sputum after its prescription as expected. However, one subject unexpectedly had 237 Elexacaftor present in their lung sputum prior to clinical knowledge of administration of ETI. The 238 presence of Ivacaftor and Tezacaftor in the sputum of pwCF prior to administration of ETI led to the 239 investigation of whether or not the presence of previously approved correctors/potentiators in sputum 240 prior to administration of ETI may have buffered the microbiome dynamics observed. Ivacaftor (a 241 component of Kalydeco®, Orkambi®, and Symdeko®) was found in 11 of the 24 patients prior to ETI 242 therapy. There was no significant difference in the alpha or beta-diversity changes between subjects 243 that had lvacaftor in their sputum prior to ETI and those that did not (p>0.05, Fig. S1). This indicates 244 that prior CFTR corrector/potentiator therapy was not contributing significantly to the overall changes 245 seen with ETI in this study, allowing these changes to be definitively attributed to this specific triple 246 therapy

247

Microbiome/Metabolite Associations Through ETI Therapy. To associate microbiome and metabolome dynamics across the dataset, we employed mmvec. This is a novel algorithm robust to the challenges of compositionality of omics datasets that calculates conditional probabilities of the association between all ASVs in the microbiome data with all metabolite features. The overall neural network showed a strong association between a changing microbiome and metabolome (Fig. S2). Additionally, the biplot of the mmvec algorithm enabled visualization of the microbiome vectors associated with the metabolomic space. In the biplot, a clear separation in vector directionality was

255 found between pathogen and anaerobe associations with the metabolome. This indicates that the 256 metabolites that change in association pathogens are not the same metabolites that associate with 257 changing anaerobes. Drivers of the metabolite changes associated with pathogens were mostly 258 peptides (Fig. 5a); those same peptides shown to be decreasing after ETI therapy. Plotting the 259 conditional probabilities of each peptide with the mean of all pathogens and all anaerobes in the 260 dataset showed that the peptides were significantly associated with pathogens (WSRT p<0.001) (Fig. 261 5b). Kynurenine, another metabolite found to decrease with ETI therapy, was most strongly associated 262 with pathogens. This analysis indicates the decrease of peptides and kynurenine in sputum samples 263 collected from pwCF is associated with a decrease in the relative abundance of pathogens (Fig. 5c).

### 264 **Discussion**

265 This study assessed the multi-omic changes in sputum from pwCF after administration of the 266 novel CF triple therapy ETI. This promising new therapy has shown significant improvement in lung 267 function and symptom measures of pwCF in clinical trials with great potential to improve the lives of 268 these individuals (15, 16). Improving CFTR function is a major goal of ETI therapy as it is the underlying 269 cause of CF. However, many adult patients have been living with persistent lung infections and an 270 evolving microbiome for decades. Promising as the treatment is, it is mostly unknown how the therapy 271 will affect lung infections and the chemistry of sputum. This is of paramount importance; if the microbial 272 infections in the lungs of pwCF do not clear and/or change favorably, then the full benefits of the 273 therapy may not be realized. Preliminary studies of other CFTR modulators and correctors, specifically 274 Ivacaftor which has received the most attention due to having the earliest FDA approval, have shown 275 some changes in microbial diversity measures with treatment (31), specifically in the gut (32, 33), but 276 most studies find little change in the airway microbiome (33–36). The addition of CFTR correctors, such 277 as Lumacaftor, have shown an increase in microbial diversity in the CF airways (37), but other studies 278 also show less marked responses (38). This study, to our knowledge, is the first to look specifically at 279 the microbiome and metabolome changes resulting from ETI therapy (which includes the new highly 280 effective potentiator Elexacaftor). Effects of the treatment were seen in both the microbiome and the 281 metabolome. By beta-diversity measures, the effect was stronger in the metabolome, demonstrating 282 that the drugs were altering the biochemical environment of CF mucus.

Microbial diversity increased with ETI therapy, indicating that the microbiome in the lungs of pwCF is becoming more complex. This increase was driven by a higher microbial evenness, a metric that contributes to the Shannon diversity, though the Shannon index itself did not reach statistical significance. Therefore, the lung microbiome of pwCF was not necessarily gaining new or losing old microbial members after ETI therapy, but those present became more similar in their relative

288 abundances, possibly an indication of greater community stability. The overall profiles of the 289 microbiome were significantly changed after ETI therapy and did so in a similar way, as shown by the 290 homogeneous directional movement across the first principal component axis. Despite these overall 291 changes, there was no single organisms that significantly altered from ETI therapy after multiple-292 comparisons correction. This is likely due to the widely known personalization in the CF microbiome (8, 293 39). Individuals have very different microbial profiles, so the start and endpoints from any 294 pharmaceutical treatment may not be universal across subjects. This personalization was again 295 observed here: subjects were still more similar to themselves after ETI therapy than to other subjects. A 296 larger sample size in this study may have reached statistical significance for microbial taxa of interest 297 because the trends for pathogens, such as *P. aeruginosa* and *Staphylococcus*, were showing strong 298 reductions in abundance, while anaerobes were showing an increase. Accordingly, a collective 299 comparison of the decrease in the log-ratio of the pathogen; anaerobe abundances did reach statistical 300 significance. This finding validates this approach of simplifying the microbiome to these two 301 communities and indicates that there is an overall reduction in the relative abundance of collective 302 clinical pathogens, even though not all patients have the same pathogen. There was also a trend in the 303 decreased bacterial load after ETI therapy, supporting that the increase in diversity seen from 304 microbiome measures may be associated with a decrease in total bacterial load from expectorated 305 sputum, though this too did not reach statistical significance. In summary, ETI therapy significantly 306 altered the lung microbiome, exemplified as an increased microbial evenness driven by a reduction in 307 the relative abundance of pathogens in place of an increase in the relative abundance of anaerobes. 308 This increase in anaerobes may have clinical relevance for treating lung infections in the new era of 309 highly effective CFTR modulators. The role of anaerobes within the CF lung is rather unclear as they 310 are associated with better lung function (40), but also pulmonary exacerbations (22, 23, 41). In light of 311 these findings, antibiotic treatment with more anaerobic coverage may be an effective approach to treat 312 CF infections in those prescribed ETI.

313 The metabolome showed significant changes following ETI therapy, with stronger metrics than 314 the microbiome. This was characterized by an increase in variability across subjects. Lung sputum 315 metabolomes were relatively similar prior to ETI therapy, but, when on drug, the sputum metabolomes 316 were highly diverse across subjects. These interesting chemical dynamics indicate that ETI induces a 317 sort of metabolomic turmoil within the airways of pwCF, where the lung sputum biochemistry changes 318 significantly with a highly varied outcome across individuals. However, similar to changes in the 319 microbiome, the directionality of change was uniform, indicating a common metabolomic shift driven by 320 ETI. Despite this variability, there were some uniform changes identified, particularly changes in 321 peptides, amino acids, and kynurenine metabolism. The latter was identified as an important pathway

322 associated with P. aeruginosa dynamics from Lumacaftor/Ivacaftor therapy in a previous study (38). 323 which the findings here and may be a universal consequence of CFTR modulator treatment. The 324 decrease in the overall abundance of peptides, particularly dipeptides, links these metabolites to a 325 previous study that associated them with worsening lung function (13). These peptides were shown to 326 be sourced from neutrophil elastase activity. Thus, the decrease in these metabolites with ETI therapy 327 may also represent a reduction in this inflammatory process, though inflammatory markers were not 328 measured in this study. There may be a link between the decrease in kynurenine metabolism and 329 amino acids/peptides, as it is a principal pathway for the metabolism of tryptophan in humans and 330 bacteria. The reduction of peptides in sputum may reduce their availability for pathogens, particularly P. 331 aeruginosa, to metabolize through the kynurenine pathway or others. The association of kynurenine 332 metabolism with *P. aeruginosa* in a previous CFTR modulator study supports the hypothesis that this 333 therapeutic approach may reduce these compounds and reshape the carbon source available to the 334 pathogen.

335 Microbial metabolite vector associations further supported the changing relationship between 336 peptides, kynurenine metabolism, and pathogens. This approach, robust to the statistical challenges of 337 cross-omics comparisons from compositional datasets (29, 42) in addition to identifying microbiome 338 and metabolome changes, showed that the decrease in peptides and kynurenine was associated with a 339 reduction in pathogens. In light of this finding, we propose the hypothesis that ETI therapy, and possibly 340 other CFTR modulators, reshape CF microbiome niche space by reducing peptide and amino acid 341 availability. This shift may squeeze out pathogens, which are known to preferentially metabolize amino 342 acids in CF mucus (43-46).

343 Metabolomics of complex clinical samples often identifies xenobiotics such as drugs 344 administered to patients (14). Prior CFTR modulators were detected in the clinical samples from pwCF 345 in this study, including evidence of diverse metabolism of these drugs, particularly ivacaftor. This 346 created a unique opportunity to determine whether or not the presence of a previously approved CFTR 347 modulator therapy in a patient's sputum affected the microbiome and metabolome dynamics of ETI. 348 Interestingly, there was no difference in the microbial and metabolite dynamics described between 349 those taking CFTR modulators and those not. This is evidence the significant changes described in this 350 study were driven by ETI, perhaps Elexactor itself, which is known to be a highly effective CFTR 351 potentiator. These results show promise that ETI therapy may have a particularly strong effect on the 352 CF sputum microbiome and metabolome where other CFTR modulators have not (33-36).

There are several caveats to our study, perhaps most importantly, ETI therapy is known to reduce sputum production in pwCF. It is difficult to discern if the changes we identified here are due to sputum chemical and microbial dynamics or a change in the ability to produce sputum when on CFTR

356 modulators. Instructions for expectoration were not varied before and after ETI to normalize the 357 sampling approach and all subjects in this study were able to produce sputum for collection both prior 358 to and during ETI therapy. Furthermore, the relatively small sample size may have masked some 359 specific changes, particularly with individual microbial ASVs. Larger studies of pwCF before and after 360 ETI therapy are warranted, though with the wide availability of these CFTR modulators currently makes 361 collecting ETI naïve sample difficult. Harvesting sputum samples for CF biobanks could be an effective 362 alternative. Finally, as with all untargeted metabolomics methods, a single protocol for metabolite 363 extraction and mass spectrometry analysis identifies only a fraction of the total metabolite pool. Future 364 studies on the metabolome of CF sputum in response to ETI therapy with more varied protocols may 365 reveal other important pathways that are altered by these drugs.

This study shows that the highly effective CF triple therapy ETI induces significant changes in the CF sputum microbiome and metabolome. This is exemplified by an overall reduction in pathogens compared to anaerobes in addition to reduced amino acid availability and kynurenine metabolism with therapy. This shows promise for the future of CF infection therapeutics because if pathogens are decreasing in abundance in place of anaerobes, antimicrobial therapy can be targeted to these organisms that may have less intrinsic resistance than notorious pathogens, such as *P. aeruginosa* and *S. aureus*.

373

Acknowledgements: The authors would like to thank the Spectrum Health and UC San Diego clinical teams who assisted with sample and metadata collection for this study. We would like to acknowledge funding from the National Institutes of Allergy and Infectious Diseases under R01 grant R01Al145925 awarded to PI Quinn.

378

### 379 References

- 380 1. J. C. Davies, E. W. F. W. Alton, A. Bush, Cystic fibrosis, *BMJ* **335**, 1255–1259 (2007).
- 2. J. Zielenski, Genotype and Phenotype in Cystic Fibrosis, *Respiration* **67**, 117–133 (2000).
- 382 3. R. K. Rowntree, A. Harris, The phenotypic consequences of CFTR mutations., *Ann. Hum. Genet.* **67**,
- 383 471–85 (2003).
- 4. B. Coburn, P. W. Wang, J. Diaz Caballero, S. T. Clark, V. Brahma, S. Donaldson, Y. Zhang, A.
- Surendra, Y. Gong, D. Elizabeth Tullis, Y. C. W. Yau, V. J. Waters, D. M. Hwang, D. S. Guttman, Lung microbiota across age and disease stage in cystic fibrosis, *Sci. Rep.* **5**, 10241 (2015).
- 5. L. Delhaes, S. Monchy, E. Fréalle, C. Hubans, J. Salleron, S. Leroy, A. Prevotat, F. Wallet, B.
- 388 Wallaert, E. Dei-Cas, T. Sime-Ngando, M. Chabé, E. Viscogliosi, The airway microbiota in cystic
- 389 fibrosis: a complex fungal and bacterial community--implications for therapeutic management., PLoS

- 390 One **7**, e36313 (2012).
- 6. H. R. Rabin, M. G. Surette, The cystic fibrosis airway microbiome., *Curr. Opin. Pulm. Med.* 18, 622–7
  (2012).
- 393 7. Y. W. Lim, R. Schmieder, M. Haynes, D. Willner, M. Furlan, M. Youle, K. Abbott, R. Edwards, J.
- 394 Evangelista, D. Conrad, F. Rohwer, Metagenomics and metatranscriptomics: Windows on CF-
- associated viral and microbial communities., J. Cyst. Fibros. 12, 154–164 (2013).
- 396 8. J. Zhao, P. D. Schloss, L. M. Kalikin, L. a Carmody, B. K. Foster, J. F. Petrosino, J. D. Cavalcoli, D.
- R. VanDevanter, S. Murray, J. Z. Li, V. B. Young, J. J. LiPuma, Decade-long bacterial community
- dynamics in cystic fibrosis airways., *Proc. Natl. Acad. Sci. U. S. A.* **109**, 5809–14 (2012).
- 399 9. D. J. Hassett, M. D. Sutton, M. J. Schurr, A. B. Herr, C. C. Caldwell, J. O. Matu, Pseudomonas
- 400 aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways., *Trends Microbiol.* 17,
- 401 130–8 (2009).
- 402 10. R. Manzenreiter, F. Kienberger, V. Marcos, K. Schilcher, W. D. Krautgartner, A. Obermayer, M.
- 403 Huml, W. Stoiber, A. Hector, M. Griese, M. Hannig, M. Studnicka, L. Vitkov, D. Hartl, Ultrastructural
- 404 characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy., *J.*
- 405 *Cyst. Fibros.* **11**, 84–92 (2012).
- 406 11. D. W. Reid, N. Misso, S. Aggarwal, P. J. Thompson, E. H. Walters, Oxidative stress and lipid-
- 407 derived inflammatory mediators during acute exacerbations of cystic fibrosis, *Respirology* **12**, 63–69
  408 (2007).
- 409 12. J. Yang, J. P. Eiserich, C. E. Cross, B. M. Morrissey, B. D. Hammock, Metabolomic profiling of
- 410 regulatory lipid mediators in sputum from adult cystic fibrosis patients., *Free Radic. Biol. Med.* **53**, 160–
- 411 71 (2012).
- 412 13. R. A. Quinn, S. Adem, R. H. Mills, W. Comstock, L. DeRight Goldasich, G. Humphrey, A. A.
- 413 Aksenov, A. V. Melnik, R. da Silva, G. Ackermann, N. Bandeira, D. J. Gonzalez, D. Conrad, A. J.
- 414 O'Donoghue, R. Knight, P. C. Dorrestein, Neutrophilic proteolysis in the cystic fibrosis lung correlates
- 415 with a pathogenic microbiome, *Microbiome* **7**, 23 (2019).
- 416 14. R. A. Quinn, V. V Phelan, K. L. Whiteson, N. Garg, B. A. Bailey, Y. W. Lim, D. J. Conrad, P. C.
- 417 Dorrestein, F. L. Rohwer, Microbial, host and xenobiotic diversity in the cystic fibrosis sputum
- 418 metabolome, *ISME J.* **10**, 1483–1498 (2015).
- 419 15. C. Bear, A therapy for most with cystic fibrosis, *Cell* **180**, 211 (2020).
- 420 16. K. Ridley, M. Condren, Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic
- Fibrosis Transmembrane Conductance Regulator Modulating Therapy, *J. Pediatr. Pharmacol. Ther.* 25,
  192–197 (2020).
- 423 17. H. G. M. Heijerman, E. F. McKone, D. G. Downey, E. Van Braeckel, S. M. Rowe, E. Tullis, M. A.

- 424 Mall, J. J. Welter, B. W. Ramsey, C. M. McKee, G. Marigowda, S. M. Moskowitz, D. Waltz, P. R.
- 425 Sosnay, C. Simard, N. Ahluwalia, F. Xuan, Y. Zhang, J. L. Taylor-Cousar, K. S. McCoy, V.-445-103 T.
- 426 Group, Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in
- 427 people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3
- 428 trial, *Lancet (London, England)* **394**, 1940–1948 (2019).
- 429 18. P. G. Middleton, M. A. Mall, P. Dřevínek, L. C. Lands, E. F. McKone, D. Polineni, B. W. Ramsey, J.
- 430 L. Taylor-Cousar, E. Tullis, F. Vermeulen, G. Marigowda, C. M. McKee, S. M. Moskowitz, N. Nair, J.
- 431 Savage, C. Simard, S. Tian, D. Waltz, F. Xuan, S. M. Rowe, R. Jain, V.-445-102 S. Group, Elexacaftor-
- 432 Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele, *N. Engl. J. Med.* 381, 1809–
  433 1819 (2019).
- 434 19. A. Gonzalez, J. A. Navas-Molina, T. Kosciolek, D. McDonald, Y. Vázquez-Baeza, G. Ackermann, J.
- 435 DeReus, S. Janssen, A. D. Swafford, S. B. Orchanian, J. G. Sanders, J. Shorenstein, H. Holste, S.
- 436 Petrus, A. Robbins-Pianka, C. J. Brislawn, M. Wang, J. R. Rideout, E. Bolyen, M. Dillon, J. G.
- 437 Caporaso, P. C. Dorrestein, R. Knight, Qiita: rapid, web-enabled microbiome meta-analysis, Nat.
- 438 *Methods* **15**, 796–798 (2018).
- 439 20. E. Bolyen, J. R. Rideout, M. R. Dillon, N. A. Bokulich, C. Abnet, G. A. Al Ghalith, H. Alexander, E. J.
- 440 Alm, M. Arumugam, Y. Bai, J. E. Bisanz, K. Bittinger, A. Brejnrod, J. Colin, C. T. Brown, B. J. Callahan,
- 441 A. Mauricio, C. Rodríguez, J. Chase, E. Cope, R. Da Silva, P. C. Dorrestein, G. M. Douglas, C.
- 442 Duvallet, C. F. Edwardson, M. Ernst, J. Fouquier, J. M. Gauglitz, D. L. Gibson, A. Gonzalez, G. A.
- 443 Huttley, S. Janssen, A. K. Jarmusch, B. D. Kaehler, K. Bin Kang, C. R. Keefe, P. Keim, S. T. Kelley, R.
- Ley, E. Loftfield, C. Marotz, B. Martin, D. Mcdonald, L. J. Mciver, V. Alexey, J. L. Metcalf, S. C. Morgan,
- J. T. Morton, A. T. Naimey, QIIME 2□: Reproducible , interactive , scalable , and extensible microbiome
  data science, *PeerJ Prepr.* (2018), doi:10.7287/peerj.preprints.27295v2.
- 447 21. A. Amir, D. McDonald, J. A. Navas-Molina, E. Kopylova, J. T. Morton, Z. Zech Xu, E. P. Kightley, L.
- 448 R. Thompson, E. R. Hyde, A. Gonzalez, R. Knight, Deblur Rapidly Resolves Single-Nucleotide
- 449 Community Sequence Patterns, *mSystems* **2** (2017) (available at
- 450 http://msystems.asm.org/content/2/2/e00191-16).
- 451 22. R. Raghuvanshi, K. Vasco, Y. Vázquez-Baeza, L. Jiang, J. T. Morton, D. Li, A. Gonzalez, L.
- 452 DeRight Goldasich, G. Humphrey, G. Ackermann, A. D. Swafford, D. Conrad, R. Knight, P. C.
- 453 Dorrestein, R. A. Quinn, N. Chia, Ed. High-Resolution Longitudinal Dynamics of the Cystic Fibrosis
- 454 Sputum Microbiome and Metabolome through Antibiotic Therapy, *mSystems* **5**, e00292-20 (2020).
- 455 23. L. A. Carmody, L. J. Caverly, B. K. Foster, M. A. M. Rogers, L. M. Kalikin, R. H. Simon, D. R.
- 456 VanDevanter, J. J. LiPuma, S. H. Chotirmall, Ed. Fluctuations in airway bacterial communities
- 457 associated with clinical states and disease stages in cystic fibrosis, *PLoS One* **13**, e0194060 (2018).

- 458 24. T. Pluskal, S. Castillo, A. Villar-Briones, M. Orešič, MZmine 2: Modular framework for processing,
- visualizing, and analyzing mass spectrometry-based molecular profile data, *BMC Bioinformatics* 11,
  395 (2010).
- 461 25. M. Wang, J. J. Carver, V. V. Phelan, L. M. Sanchez, N. Garg, Y. Peng, D. D. Nguyen, J. Watrous,
- 462 C. A. Kapono, T. Luzzatto-Knaan, C. Porto, A. Bouslimani, A. V. Melnik, M. J. Meehan, W.-T. Liu, M.
- 463 Crüsemann, P. D. Boudreau, E. Esquenazi, M. Sandoval-Calderón, R. D. Kersten, L. A. Pace, R. A.
- 464 Quinn, K. R. Duncan, C.-C. Hsu, D. J. Floros, R. G. Gavilan, K. Kleigrewe, T. Northen, R. J. Dutton, D.
- 465 Parrot, E. E. Carlson, B. Aigle, C. F. Michelsen, L. Jelsbak, C. Sohlenkamp, P. Pevzner, A. Edlund, J.
- 466 McLean, J. Piel, B. T. Murphy, L. Gerwick, C.-C. Liaw, Y.-L. Yang, H.-U. Humpf, M. Maansson, R. A.
- 467 Keyzers, A. C. Sims, A. R. Johnson, A. M. Sidebottom, B. E. Sedio, A. Klitgaard, C. B. Larson, C. A. P.
- Boya, D. Torres-Mendoza, D. J. Gonzalez, D. B. Silva, L. M. Marques, D. P. Demarque, E. Pociute, E.
- 469 C. O'Neill, E. Briand, E. J. N. Helfrich, E. A. Granatosky, E. Glukhov, F. Ryffel, H. Houson, H.
- 470 Mohimani, J. J. Kharbush, Y. Zeng, J. A. Vorholt, K. L. Kurita, P. Charusanti, K. L. McPhail, K. F.
- 471 Nielsen, L. Vuong, M. Elfeki, M. F. Traxler, N. Engene, N. Koyama, O. B. Vining, R. Baric, R. R. Silva,
- 472 S. J. Mascuch, S. Tomasi, S. Jenkins, V. Macherla, T. Hoffman, V. Agarwal, P. G. Williams, J. Dai, R.
- 473 Neupane, J. Gurr, A. M. C. Rodríguez, A. Lamsa, C. Zhang, K. Dorrestein, B. M. Duggan, J. Almaliti,
- 474 P.-M. Allard, P. Phapale, L.-F. Nothias, T. Alexandrov, M. Litaudon, J.-L. Wolfender, J. E. Kyle, T. O.
- 475 Metz, T. Peryea, D.-T. Nguyen, D. VanLeer, P. Shinn, A. Jadhav, R. Müller, K. M. Waters, W. Shi, X.
- Liu, L. Zhang, R. Knight, P. R. Jensen, B. Ø. Palsson, K. Pogliano, R. G. Linington, M. Gutiérrez, N. P.
- 477 Lopes, W. H. Gerwick, B. S. Moore, P. C. Dorrestein, N. Bandeira, Sharing and community curation of
- 478 mass spectrometry data with Global Natural Products Social Molecular Networking, *Nat. Biotechnol.* **34**
- 479 (2016), doi:10.1038/nbt.3597.
- 480 26. K. Dührkop, M. Fleischauer, M. Ludwig, A. A. Aksenov, A. V Melnik, M. Meusel, P. C. Dorrestein, J.
- 481 Rousu, S. Böcker, SIRIUS 4: a rapid tool for turning tandem mass spectra into metabolite structure
- 482 information, *Nat. Methods* **16**, 299–302 (2019).
- 483 27. Y. Vázquez-Baeza, M. Pirrung, A. Gonzalez, R. Knight, EMPeror: a tool for visualizing high-
- 484 throughput microbial community data., *Gigascience* **2**, 16 (2013).
- 485 28. L. Breiman, Random Forests, *Mach. Learn.* **45**, 5–32 (2001).
- 486 29. J. T. Morton, A. A. Aksenov, L. F. Nothias, J. R. Foulds, R. A. Quinn, M. H. Badri, T. L. Swenson,
- 487 M. W. Van Goethem, T. R. Northen, Y. Vazquez-Baeza, M. Wang, N. A. Bokulich, A. Watters, S. J.
- 488 Song, R. Bonneau, P. C. Dorrestein, R. Knight, Learning representations of microbe-metabolite
- 489 interactions, *Nat. Methods*, 1–9 (2019).
- 490 30. F. Reyes-Ortega, F. Qiu, E. K. Schneider-Futschik, Multiple Reaction Monitoring Mass
- 491 Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in

- 492 Cystic Fibrosis: A High-Throughput Method, ACS Pharmacol. Transl. Sci. 3, 987–996 (2020).
- 493 31. N. J. Ronan, G. G. Einarsson, M. Twomey, D. Mooney, D. Mullane, M. NiChroinin, G. O'Callaghan,
- 494 F. Shanahan, D. M. Murphy, O. J. O'Connor, C. A. Shortt, M. M. Tunney, J. A. Eustace, M. M. Maher,
- 495 J. S. Elborn, B. J. Plant, CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose
- 496 Chest CT Scores After CFTR Modulation With Ivacaftor, *Chest* **153**, 395–403 (2018).
- 497 32. C. Y. Ooi, S. A. Syed, L. Rossi, M. Garg, B. Needham, J. Avolio, K. Young, M. G. Surette, T.
- 498 Gonska, Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation, *Sci.*
- 499 *Rep.* **8**, 17834 (2018).
- 500 33. M. I. Kristensen, K. M. de Winter-de Groot, G. Berkers, M. L. J. N. Chu, K. Arp, S. Ghijsen, H. G. M.
- 501 Heijerman, H. G. M. Arets, C. J. Majoor, H. M. Janssens, R. van der Meer, D. Bogaert, C. K. van der
- 502 Ent, Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in
- 503 People with CF and a S1251N Mutation., *J. Pers. Med.* **11** (2021), doi:10.3390/jpm11050350.
- 504 34. J. K. Harris, B. D. Wagner, E. T. Zemanick, C. E. Robertson, M. J. Stevens, S. L. Heltshe, S. M.
- 505 Rowe, S. D. Sagel, Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in
- 506 Patients with Cystic Fibrosis and the G551D Mutation, Ann. Am. Thorac. Soc. 17, 212–220 (2019).
- 507 35. A. Y. Peleg, J. M. Choo, K. M. Langan, D. Edgeworth, D. Keating, J. Wilson, G. B. Rogers, T.
- 508 Kotsimbos, Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory 509 microbiota composition, *J. Cyst. Fibros.* **17**, 50–56 (2018).
- 510 36. C. Bernarde, M. Keravec, J. Mounier, S. Gouriou, G. Rault, C. Férec, G. Barbier, G. Héry-Arnaud,
- 511 Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a
- 512 G551D mutation., *PLoS One* **10**, e0124124 (2015).
- 513 37. S. Y. Graeber, S. Boutin, M. O. Wielpütz, C. Joachim, D. L. Frey, S. Wege, O. Sommerburg, H.-U.
- 514 Kauczor, M. Stahl, A. H. Dalpke, M. A. Mall, Effects of Lumacaftor-Ivacaftor on Lung Clearance Index,
- 515 Magnetic Resonance Imaging and Airway Microbiome in Phe508del Homozygous Patients with Cystic
- 516 Fibrosis, Ann. Am. Thorac. Soc. (2021), doi:10.1513/AnnalsATS.202008-1054OC.
- 517 38. A. H. Neerincx, K. Whiteson, J. L. Phan, P. Brinkman, M. I. Abdel-Aziz, E. J. M. Weersink, J.
- 518 Altenburg, C. J. Majoor, A. H. Maitland-van der Zee, L. D. J. Bos, Lumacaftor/ivacaftor changes the
- 519 lung microbiome and metabolome in cystic fibrosis patients, *ERJ Open Res.* **7**, 731–2020 (2021).
- 39. S. V Lynch, K. D. Bruce, The cystic fibrosis airway microbiome., *Cold Spring Harb. Perspect. Med.*3, a009738 (2013).
- 40. C. Lamoureux, C.-A. Guilloux, C. Beauruelle, A. Jolivet-Gougeon, G. Héry-Arnaud, Anaerobes in cystic fibrosis patients' airways, *Crit. Rev. Microbiol.* **45**, 103–117 (2019).
- 41. R. A. Quinn, K. Whiteson, Y.-W. Lim, P. Salamon, B. Bailey, S. Mienardi, S. E. Sanchez, D. Blake,
- 525 D. Conrad, F. Rohwer, A Winogradsky-based culture system shows an association between microbial

526 fermentation and cystic fibrosis exacerbation, *ISME J.* **9** (2015), doi:10.1038/ismej.2014.234.

- 42. G. B. Gloor, J. M. Macklaim, V. Pawlowsky-Glahn, J. J. Egozcue, Microbiome Datasets Are
- 528 Compositional: And This Is Not Optional, *Front. Microbiol.* **8**, 2224 (2017).
- 529 43. J. M. Flynn, D. Niccum, J. M. Dunitz, R. C. Hunter, Evidence and Role for Bacterial Mucin
- 530 Degradation in Cystic Fibrosis Airway Disease, *PLoS Pathog.* **12**, 1–21 (2016).
- 531 44. S. R. Thomas, A. Ray, M. E. Hodson, T. L. Pitt, Increased sputum amino acid concentrations and
- auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease., *Thorax* 55, 795–7
  (2000).
- 45. A. L. BARTH, T. L. PITT, The high amino-acid content of sputum from cystic fibrosis patients
- 535 promotes growth of auxotrophic Pseudomonas aeruginosa, *J. Med. Microbiol.* **45**, 110–119 (1996).
- 536 46. R. A. Quinn, Y. W. Lim, H. Maughan, D. Conrad, F. Rohwer, K. L. Whiteson, Biogeochemical forces
- 537 shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung, *MBio* **5**
- 538 (2014), doi:10.1128/mBio.00956-13.
- 539

# 540 Figure Legends.

541

542 Fig. 1. Alpha and Beta-diversity of Lung microbiomes before and after ETI. Alpha-diversity measures of 543 a) microbiome data and b) metabolome data before (N ETI) and after ETI therapy. P-values shown are 544 from either the DM t-test or WSRT after testing for normality. Principal coordinate analysis plots of beta-545 diversity data for c) microbiome data with significance calculated utilizing the weighted UniFrac distance 546 and d) metabolome data with significance calculated utilizing the Bray-Curtis distance. PERMANOVA 547 statistics and the percent of variance explained by each axis are shown. Boxplots of positions on the 548 first principal coordinate are shown tested for significance with the DM t-test. Beta-diversity cross 549 comparisons within the e) microbiome and f) metabolome data. Cross comparisons were done across 550 patients before and after ETI therapy, across the entire dataset, and within subjects before and after 551 ETI therapy (within). Statistical significance was first tested with an ANOVA followed by an ad-hoc 552 Tukey's test. Shared letters denote distributions that are significantly different from each other. 553

- **Fig. 2.** *Microbiome changes throughout ETI therapy.* a) Taxonomic dynamics at the family level of ASVs in each subject before (N) and after (T) ETI therapy. b) The rRNA copies/mL of sputum, logration of pathogen:anaerobes and ASV dynamics before and after ETI therapy.
- 557

Fig. 3. Metabolite network of peptides and other metabolite changes. a) Molecular family metabolite
abundance changes pre- and post-therapy. b) Individual metabolite changes pre- and post-therapy. c)

560 Molecular network of peptides identified by GNPS library searching. Each node represents a unique 561 MS/MS spectrum (putative metabolite), connections between the nodes are determined and width-562 scaled by the cosine score from MS/MS alignment. Pie charts are the total feature abundance colored 563 according to the legend.

564

565 Fig. 4. ETI metabolism detected in sputum metabolomic data. a) Three separate molecular networks 566 are shown for Ivacaftor, Tezacaftor, or Elexacaftor and their related metabolic products as identified by 567 MS/MS spectral alignments. Each node in a network represents a unique MS/MS spectrum and 568 connections between the nodes indicate spectral similarity as identified by the cosine score. The width 569 of the edges are scaled to the cosine score and the pie chart inside nodes represent the sum of the 570 area-under-curve abundance of that molecule in either pre- (red) or post-treatment (blue) sputum 571 samples. The nodes are highlighted by whether they represent parent drug, known metabolized product, or putative unknown metabolized product. Putative structures of the metabolites are shown 572 573 with their molecular formulas, retention times, and exact masses. Note that the stereochemistry of 574 some of the metabolized products cannot be discerned with this level of MS/MS annotation. b) Boxplots 575 of the area-under-curve abundance of the three parent drugs in pre- and post-ETI samples.

576

577 Fig. 5. Mmvec analysis of sputum microbiomes and metabolomes from pwCF. a) Biplot of the 578 metabolite and microbe vector associations. Each diamond represents a metabolite (only metabolites 579 annotated within the GNPS library are shown) and they are colored by their molecular family. The 580 vectors are the top 15 ASVs associated with the metabolomic dynamics and they are colored by 581 whether or not they are considered clinical pathogens or anaerobes. b) Conditional probability 582 distributions for the mean of all peptides identified in the dataset and their association with either 583 anaerobes (red) or pathogens (purple, p-value from DM T-test). c) Rank abundance of the conditional 584 probabilities of kynurenine with different anaerobes (red) and pathogens (purple) ASVs.









ткт

ткт

ткт

